This study is a chart review of patients with Chronic Myelogenous Leukemia (CML), a type of blood cancer, who have been treated with medications like imatinib, dasatinib, or nilotinib outside of a clinical trial at MD Anderson Cancer Center. Researchers are looking at existing medical records to understand how these standard-dose treatments work for a large group of patients. The goal is to see how patients respond to imatinib, specifically looking at their progress up to June 2012. You may be eligible if you have CML in any phase and have received treatment with an FDA-approved tyrosine kinase inhibitor (like imatinib) and had at least one visit at MDACC.

Study design

This is an observational study that will review the medical charts of up to 3000 patients. It is not a clinical trial where new treatments are tested.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Patient response to imatinib will be measured up to June 2012.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.